108.40
0.80 (0.74%)
| Penutupan Terdahulu | 107.60 |
| Jumlah Dagangan | 1,300,441 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.62 |
| Harga / Jualan (P/S) | 3.74 |
| Harga / Buku (P/B) | 5.89 |
| Julat 52 Minggu |
| Margin Keuntungan | 12.32% |
| Margin Operasi (TTM) | 17.20% |
| EPS Cair (TTM) | 3.31 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 184.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 156.35% |
| Nisbah Semasa (MRQ) | 1.62 |
| Aliran Tunai Operasi (OCF TTM) | 181.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 183.89 M |
| Pulangan Atas Aset (ROA TTM) | 6.65% |
| Pulangan Atas Ekuiti (ROE TTM) | 18.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Haemonetics Corporation | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.44 |
|
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.10% |
| % Dimiliki oleh Institusi | 118.44% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |